Neurol. praxi. 2022;23(4):319-322

The influence of aging on course multiple sclerosis on climacteric and menopausal women

MUDr. Olga Zapletalová
Neurologická klinika FN Ostrava a LF OU, Ostrava

Multiple sclerosis is a chronic inflammatory disease of the central nervous system leading to demyelination and neurodegeneration. The disease is clearly more common in women. Being a women is one of the strongest risk factors for multiple sclerosis. Menopause is one of the evolutionary stages that all women experience trough aging and this fenomenon exposes them to massive changes. Boath healthy and RS women could have some healthy problems. In clinical practice, symptoms of MS and menopause can frequently overlap. The presence of MS does not appear to influence age of menopausal onset, but MS disability during and after menopause seems to worsen. Mechanisms through which menopausal MS women experience disability progression include neuroinflammation and neurodegeneraration from age associated phenomena. Menopause - related declines in sex hormone levels may contribute to a reproductive senescence. An immportant factor to age-related MS disability progression is immunosenescence. Premature ovarian failure is defined as hypergonadotropic amenorrhoea, has a diverse etiology and autoimunity may play a role.

Keywords: multiple sclerosis, menopause, disability, reproductive senescence, premature ovarian failure.

Accepted: August 18, 2022; Published: August 30, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zapletalová O. The influence of aging on course multiple sclerosis on climacteric and menopausal women. Neurol. praxi. 2022;23(4):319-322.
Download citation

References

  1. Baroncini D, Annovazzi PO, De Rossi N, et al. Impact of natural menopause on multiple sclerosis: a multicentre study. J Neurol Neurosurg Psychiatry. 2019;90:1201-1206. Go to original source... Go to PubMed...
  2. Bove R. Autoimmune diseases and reproductive aging. Clin Immunol. 2013;149:251-264. Go to original source... Go to PubMed...
  3. Bove R, Okal A, Houtchens M, et al. Effects of menopause in women with multiple sclerosis: An Evidence-Based Review. Front Neurol. 2021;12:554375. Go to original source... Go to PubMed...
  4. Bove R, Healy BC, Musallam A, et al. Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort. Mult Scler. 2016;22:935-943. Go to original source... Go to PubMed...
  5. Ferrell RJ, O´Connor KA, Rodriguez G, et al. Monitoring reproductive aging in a 5-year prospective study: aggregate and individual changes in steroid hormones and menstrual cycle lenghts with age. Menopause. 2005;12:567-577. Go to original source... Go to PubMed...
  6. Gava G, Visconti M, Salvi F, et al. Prevalence andpsychiothological determinants of sexual dysfunction and related distress in women with and without multiple sclerosis. J Sex Med. 2019;16:833-842. Go to original source... Go to PubMed...
  7. Graves JS, Henry RG, Cree BAC, et al. Ovarian aging is associated with gray matter volume and disability in women with MS. Neurology. 2018;90:e254-260. Go to original source... Go to PubMed...
  8. Grossmann B, Saur S, Rall K, et al. Prevalence of autoimmu­ne disease in women with premature ovarian failure. The Euro­pean Journal of Contraception & Reproductive Health Care. 2020;25(1):70-75. Go to original source... Go to PubMed...
  9. Heidari M, Ghodusi M, Rezaei P, et al. Sexual function and factors affecting menopause: a systematic review. J Menopausal Med. 2019;25:15-27. Go to original source... Go to PubMed...
  10. Kelsey TW, Wright P, Nelson SM, et al. A validated model of serum anti-müllerian hormone from conception to menopause. PLoS One. 2011;6:e22024. Go to original source... Go to PubMed...
  11. Koliba P, Zapletalová O, Hradílek P. Roztroušená skleróza u žen a menopauza. Klimakterická medicína. 2009;14:19-20.
  12. Koliba P. Roztroušená skleróza mozkomíšní a menopauza. Neurol. praxi. 2011; 12(4):282-285.
  13. Midaglia L, Otero S, Baró F, et al. Menopause and multiple sclerosis: Influence on prognosis and role of disease-modifying drugs and hormonal replacement therapy. Mult Scler. 2020. doi: 10.1177/1352458520952022. Go to original source... Go to PubMed...
  14. Musella A, Gentile A, Rizzo FR, et al. Interplay between age and neuroinflammation in multiple sclerosis: effects on motor and cognitive functions. Front Aging Neurosci. 2018;10:238. Go to original source... Go to PubMed...
  15. Ngo ST, Steyn FJ, McCombe PA. Gender differences in auto­immune disease. Front Neuroendocrinol. 2014;35:347-369. Go to original source... Go to PubMed...
  16. Prokopová I, Crha I. Předčasné ovariální selhání. Prakt Gyn. 2007;11(4):170-173.
  17. Ruano L, Portaccio E, Goretti B, Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes. Mult Scler. 2017;23:1258-1267. Go to original source... Go to PubMed...
  18. Sparaco M, Bonavita S. The role of sex hormones in women with multiple sclerosis: From puberty to assisted reproductive techniques. Front Neuroendocrinol. 2021;60:100889. Go to original source... Go to PubMed...
  19. Weinstein RS. Glucocorticoid induced osteoporo­sis and osteonecrosis. Endocrinol Metab Clin North America. 2012;41:595-611. Go to original source... Go to PubMed...
  20. Ysrraelit MC, Correale J. Impact of sex hormones on immune function and multiple sclerosis development. Immunology. 2019;156:9-22. Go to original source... Go to PubMed...
  21. Zeydan B, Atkinson EJ, Weis DM, et al. Reproductive history and progressive multiple sclerosis risk in women. Brain Commun. 2020; 17(2):185. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.